Archives: News

Central Idea

• In the wake of the recent Hamas attack on Israel, the world witnessed the effectiveness of Israel’s Iron Dome, a remarkable air defense system that intercepts rockets and missiles aimed at Israeli targets.

What is Iron Dome?

• Hezbollah’s Rocket Attacks: The development of the Iron Dome traces back to the 2006 Israeli-Lebanon war when Hezbollah launched thousands of rockets into Israel.
• Israel’s Response: In 2007, Israel initiated the development of an air defense system to safeguard its cities and population, partnering with Rafael Advance Systems and Israel Aerospace Industries.
• Deployment: The Iron Dome became operational in 2011 and has since intercepted over 2,000 rockets, with a claimed success rate of over 90%, though experts estimate it at over 80%.

How does it work?

• Integrated Systems: The Iron Dome comprises three core components that work in unison to provide protection: detection and tracking radar, battle management and weapon control system (BMC), and missile firing units.
• Radar’s Role: The detection and tracking radar identifies incoming threats, accurately tracking them, while the BMC connects the radar and interceptor missile.
• Missile Firing Unit: Once launched, the missile maneuvers independently, targeting small objects, and employs a proximity fuse, activated within ten meters of the target, to ensure precise destruction.

Effectiveness and Deterrence

• All-Weather Capability: The Iron Dome operates effectively in various weather conditions, day and night, enhancing its reliability.
• Cost Considerations: While each battery can cost over $50 million, and an interceptor Tamir missile about $80,000, cost-effectiveness should be measured in terms of lives saved and the nation’s morale.
• Deterrence Factor: The Iron Dome serves as a strong deterrent, preventing adversaries from exploiting inexpensive rocket attacks and bolstering national morale against rocket intimidation.

Central Idea

• Scientists from Thailand are conducting groundbreaking research into the potential of watermeal, the world’s smallest flowering plant, as a source of nutrition and oxygen for astronauts.

What are Watermeal?

• Watermeal, a member of the Araceae family, stands out as the smallest flowering plant globally.
• It manifests as minuscule green seeds.
• Watermeal thrives in a variety of environments, from temperate to sub-tropical and tropical regions. It finds its home on the surface of lakes, ponds, and marshes.
• Distinctive Features:
  1. Measuring less than 1 millimeter, watermeal is incredibly tiny.
  2. This free-floating plant lacks both roots and leaves.
  3. It consists of a solitary, oval, or spherical frond that gracefully floats on the calm or slow-moving waters.
  4. Watermeal gives birth to the world’s smallest fruit, known as a utricle.
  5. Surprisingly, watermeal is a nutritional powerhouse, boasting the status of a complete protein, as it contains all nine essential amino acids.
  6. Under certain circumstances, watermeal can become invasive, forming dense mats that blanket entire water surfaces.

How it can assist Space Nutrition?

• Compact Growth: Its microscopic size allows for efficient cultivation within confined spacecraft environments.
• Nutritional Richness: As a complete protein, it offers astronauts a sustainable source of essential amino acids.
• Oxygen Generation: Watermeal photosynthesizes, producing oxygen that can be vital for life support systems in space.
• Space Farming: Cultivating watermeal in space could reduce the need for transporting perishable food items from Earth, making missions more self-sustaining.

Central Idea

• In a momentous development in the fight against malaria, the World Health Organization (WHO) issued a recommendation for the R21/Matrix-M malaria vaccine on October 2.
• This pioneering vaccine, developed by the University of Oxford and manufactured by India’s Serum Institute, has already gained approval for use in children under 36 months in Nigeria, Ghana, and Burkina Faso.

R21/Matrix-M Vaccine

• Extensive Testing: The vaccine’s efficacy was rigorously assessed in a phase-3 trial involving 4,800 children across five sites in Mali, Burkina Faso, Kenya, and Tanzania. These sites vary in malaria transmission intensity and seasonality.
• Blind Trial: Participants were randomly assigned to receive either the malaria vaccine or a control (approved rabies vaccine) in a double-blind study, ensuring impartiality.
• Multi-Dose Regimen: The vaccination schedule comprised three doses administered 4 weeks apart, with a booster shot administered 12 months after the last dose.
• Strategic Timing: Primary vaccinations occurred before the malaria season in seasonal transmission regions or at any time of the year in perennial transmission regions.

Impressive Results

• According to preprint data (pending peer review), the vaccine demonstrated a remarkable efficacy of 75% in children aged 5-36 months in seasonal malaria regions and 68% in perennial malaria regions after one year.
•  Notably, children aged 5-17 months, more vulnerable to severe malaria, exhibited even higher vaccine efficacy of 79% in seasonal regions and 75% in perennial regions.
• Vaccine efficacy remained substantial for 18 months, further reinforced by a booster dose administered 12 months after the primary series.

Seasonality Matters

• Optimal Timing: Results suggest that the vaccine performs more effectively in regions with seasonal malaria compared to perennial transmission areas.
• Seasonal Patterns: In seasonal sites, 82% of malaria episodes occurred in the first six months of follow-up, while only 26% occurred in the initial six months in perennial sites.
• Vaccination Timing: Since the vaccine is administered just before the malaria season, its protection is more pronounced when malaria is seasonal.